T
Talquetamab [Talvey]
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Patient Alert Card
Subsidy Information and Financing Scheme
No
Active ingredient: Talquetamab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
06/02/2026 Talquetamab for relapsed or refractory multiple myeloma
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended talquetamab for inclusion on the MOH List of Subsidised Drugs for treating relapsed or refractory multiple myeloma in patients who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-cluster of differentiation 38 antibody, and have demonstrated disease progression on the last therapy. The decision was based on the uncertainty surrounding the extent of talquetamab’s comparative effectiveness, unacceptable cost effectiveness compared with physician’s choice of treatment, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for talquetamab are provided in the Annex.
Post Marketing Information
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Subcutaneous
* Clinical information is available for this product.